Clinical Trial Update: A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 study of LY3295668 Erbumine in participants with relapsed/refractory neuroblastoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• LY3295668 Erbumine (Erbumine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Neuroblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING